By Ransdell Pierson
(Reuters) - Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available this month, which would make it one of the world's most expensive cancer drugs.
Company spokeswoman Danielle Bertrand said the price for the infused medicine, called Blincyto, would reflect two courses of treatment, at $89,000 per cycle.
U.S. regulators on Dec. 3 approved the Amgen drug more than five months ahead of the expected decision date, to treat a blood cancer called acute lyphoblastic leukemia, for which there are few options once a patient has relapsed following standard treatment.
(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app